Jim Cramer's top 10 things to watch in the stock market Monday

U.S. equity futures rose on a rebound after dovish comments from New York Fed President John Williams lifted hopes for a December rate cut, even as the S&P 500 finished the month down ~3.5%; delayed September retail sales and producer price data and the Thanksgiving-shortened week are focal macro events. On the corporate front, Novo Nordisk plunged >10% to a four‑year low after semaglutide failed an Alzheimer’s trial, while several analyst moves signaled upside for other names: Bernstein raised Eli Lilly’s target to $1,300 citing upcoming oral GLP‑1 Orforglipron and international expansion, Wells Fargo upgraded Merck and raised its target to $125, and firms initiated/raised coverage on Carvana, Lemonade, Waste Management and Cadence (Citi PT $385).

Analysis

Market structure is bifurcating: rate-sensitive equities and AI/software beneficiaries should see a modest tailwind if markets price a higher December cut probability, supporting higher multiple expansion in growth names while cyclical consumer stocks get a pulse if data confirms demand. Healthcare GLP‑1 dynamics now favor differentiated pipelines and commercial execution—winners will be firms with oral GLP‑1s and broad international channels; losers are those with near-term binary trial risk or concentrated revenue exposure. Supply/demand imbalances will show in fixed income (higher duration demand, tighter yields on dovish messaging) and in options (skewed put buying in beaten-up biotechs), while a softer USD would lift commodity/inflation-sensitive stocks and EM assets.

Tail risks center on three low‑probability/high‑impact events: (1) further negative clinical readouts or regulatory action that cascades through GLP‑1 adopters, (2) a Fed that signals no December cut despite dovish talk, re-pricing rates higher quickly, and (3) idiosyncratic operational shocks at leveraged consumer names. Timing matters—expect immediate volatility into retail sales/PPI and Fed minutes (days–weeks), structural earnings and product launches to drive outcomes over months, and secular GLP‑1/AI adoption shaping revenue trajectories over 12–36 months. Hidden dependencies include pharma pricing negotiations, inventory corrections at retailers, and option gamma into month‑end that can exaggerate moves.

Trade implications: take tactical long exposure to Eli Lilly (LLY) ahead of oral GLP‑1 commercialization and international expansion while sizing conservatively (1–3%); pair that with a small disciplined short or put spread on the most exposed GLP‑1 incumbent to express dispersion. Buy defensive/compounder exposure in Waste Management (WM) 1–2% for 6–12 months to capture steady cashflow and M&A optionality; rotate 4–6% from cash into 7–10yr Treasuries or TLT if 10yr yields breach downwards (e.g., <3.8%) on Fed pricing. Use short‑dated (30–60 day) put spreads on high‑vol biotech names to exploit skew while selling covered call or call spreads on richly priced AI beneficiaries to finance exposure.

Contrarian angles: consensus may be over‑penalizing single trial failures—market often overshoots on headlines and then re-rates on recurring revenues and label expansion, creating buying windows 4–12 weeks post‑selloff if no follow‑on negative data. Conversely, some perceived winners (LLY) may have much upside priced in; layering in options structures (call spreads) limits downside if expectations slip. Historical parallels (biotech headline crashes that reversed once sales/labels persisted) argue for measured sized re-entry rather than full conviction, and unintended consequences include cross‑sector volatility contagion that can blow out hedging costs suddenly.

Key Decisions for Investors

• Establish a 2–3% long position in Eli Lilly (LLY) sized to portfolio; set hard stop at -10% and a staged take‑profit plan at +20% (6 months) and +40% (12 months) to capture Orforglipron launch and international growth upside.
• Allocate 0.5–1.0% to a 30–60 day NVO put spread (buy 20–25% OTM puts, sell 10–15% OTM puts) as a tactical hedge against further GLP‑1 headline risk; close or roll if implied vol >80% or if share price stabilizes within 10% of entry.
• Buy 1–2% position in Waste Management (WM) for 6–12 months to capture defensive cashflow and analyst‑driven re‑rating; implement a -8% stop and a +20% target, re‑evaluate on quarterly results or M&A signals.
• Rotate 4–6% of cash into duration if market prices >50% probability of a December cut (e.g., 10yr yields <3.8%)—use Treasuries or IG long‑dated ETFs to add ~+2yrs duration, trim if yields snap back above the threshold.
• Implement a pair trade: long LLY (1.5%) vs short NVO (0.75%) net exposure for 3–9 months to express GLP‑1 relative conviction; rebalance if regulatory/FDA calendar shows definitive catalysts or if spread tightens/widens by >15%.